Cargando…
Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxygluco...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666711/ https://www.ncbi.nlm.nih.gov/pubmed/28937584 http://dx.doi.org/10.3390/ijms18102029 |
_version_ | 1783275354848231424 |
---|---|
author | Zhu, Hongyan Liu, Wanwan Cheng, Ziting Yao, Ke Yang, Yu Xu, Bohui Su, Gaoxing |
author_facet | Zhu, Hongyan Liu, Wanwan Cheng, Ziting Yao, Ke Yang, Yu Xu, Bohui Su, Gaoxing |
author_sort | Zhu, Hongyan |
collection | PubMed |
description | In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxyglucose (DG) is the targeting molecule, polyethylene glycol (PEG) helps to improve the dispersity and biocompatibility, 9-poly-d-arginine (9R) is employed to provide a positive surface charge and adsorb negative siRNA, and hydrazone bonds are pH-responsive and can avoid receptor-mediated endosomal recycling. Compared to GNS alone, 9R/DG-GNS (hydrazone) showed superior transfection efficiency. The expressions of cyclooxygenase-2 (COX-2) in HepG2 and SGC7901 cells were significantly suppressed by siRNA/9R/DG-GNS (hydrazone) complex. Notably, 9R/DG-GNS (hydrazone) possessed low cytotoxicity even at high concentrations in both normal cells and tumor cells. The combination treatment of siRNA/9R/DG-GNS (hydrazone) complex inhibited the cell growth rate by more than 75%. These results verified that the pH-responsive GNS complex is a promising siRNA delivery system for cancer therapy, and it is anticipated that near-infrared absorbing GNS with good photothermal conversion efficiency can be potentially used for photothermal therapy of tumors. |
format | Online Article Text |
id | pubmed-5666711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56667112017-11-09 Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment Zhu, Hongyan Liu, Wanwan Cheng, Ziting Yao, Ke Yang, Yu Xu, Bohui Su, Gaoxing Int J Mol Sci Article In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxyglucose (DG) is the targeting molecule, polyethylene glycol (PEG) helps to improve the dispersity and biocompatibility, 9-poly-d-arginine (9R) is employed to provide a positive surface charge and adsorb negative siRNA, and hydrazone bonds are pH-responsive and can avoid receptor-mediated endosomal recycling. Compared to GNS alone, 9R/DG-GNS (hydrazone) showed superior transfection efficiency. The expressions of cyclooxygenase-2 (COX-2) in HepG2 and SGC7901 cells were significantly suppressed by siRNA/9R/DG-GNS (hydrazone) complex. Notably, 9R/DG-GNS (hydrazone) possessed low cytotoxicity even at high concentrations in both normal cells and tumor cells. The combination treatment of siRNA/9R/DG-GNS (hydrazone) complex inhibited the cell growth rate by more than 75%. These results verified that the pH-responsive GNS complex is a promising siRNA delivery system for cancer therapy, and it is anticipated that near-infrared absorbing GNS with good photothermal conversion efficiency can be potentially used for photothermal therapy of tumors. MDPI 2017-09-22 /pmc/articles/PMC5666711/ /pubmed/28937584 http://dx.doi.org/10.3390/ijms18102029 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhu, Hongyan Liu, Wanwan Cheng, Ziting Yao, Ke Yang, Yu Xu, Bohui Su, Gaoxing Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title | Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title_full | Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title_fullStr | Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title_full_unstemmed | Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title_short | Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment |
title_sort | targeted delivery of sirna with ph-responsive hybrid gold nanostars for cancer treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666711/ https://www.ncbi.nlm.nih.gov/pubmed/28937584 http://dx.doi.org/10.3390/ijms18102029 |
work_keys_str_mv | AT zhuhongyan targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT liuwanwan targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT chengziting targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT yaoke targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT yangyu targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT xubohui targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment AT sugaoxing targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment |